CN119173255A - Glp1药物组合物 - Google Patents

Glp1药物组合物 Download PDF

Info

Publication number
CN119173255A
CN119173255A CN202380039380.7A CN202380039380A CN119173255A CN 119173255 A CN119173255 A CN 119173255A CN 202380039380 A CN202380039380 A CN 202380039380A CN 119173255 A CN119173255 A CN 119173255A
Authority
CN
China
Prior art keywords
fluoro
composition
amount
oxadiazol
methylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039380.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·J·伯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN119173255A publication Critical patent/CN119173255A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380039380.7A 2022-05-11 2023-05-10 Glp1药物组合物 Pending CN119173255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN119173255A true CN119173255A (zh) 2024-12-20

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039380.7A Pending CN119173255A (zh) 2022-05-11 2023-05-10 Glp1药物组合物

Country Status (16)

Country Link
US (1) US20250302809A1 (enExample)
EP (1) EP4522129A1 (enExample)
JP (1) JP7767651B2 (enExample)
KR (1) KR20250002778A (enExample)
CN (1) CN119173255A (enExample)
AR (1) AR129296A1 (enExample)
AU (1) AU2023269995A1 (enExample)
CA (1) CA3253043A1 (enExample)
CL (1) CL2024003392A1 (enExample)
CO (1) CO2024015285A2 (enExample)
DO (1) DOP2024000232A (enExample)
IL (1) IL316629A (enExample)
MX (1) MX2024013839A (enExample)
PE (1) PE20251285A1 (enExample)
TW (2) TWI867526B (enExample)
WO (1) WO2023220109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
EP3984523B1 (en) * 2018-12-07 2025-09-03 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
UY38696A (es) * 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
SMT202500315T1 (it) * 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina
KR20250002779A (ko) * 2022-05-11 2025-01-07 일라이 릴리 앤드 캄파니 Glp1 정제 조성물

Also Published As

Publication number Publication date
US20250302809A1 (en) 2025-10-02
TW202410894A (zh) 2024-03-16
CA3253043A1 (en) 2023-11-16
MX2024013839A (es) 2024-12-06
WO2023220109A1 (en) 2023-11-16
KR20250002778A (ko) 2025-01-07
AU2023269995A1 (en) 2024-11-14
IL316629A (en) 2024-12-01
PE20251285A1 (es) 2025-05-14
CO2024015285A2 (es) 2024-11-28
JP7767651B2 (ja) 2025-11-11
CL2024003392A1 (es) 2025-03-14
TW202508581A (zh) 2025-03-01
AR129296A1 (es) 2024-08-07
JP2025515706A (ja) 2025-05-20
DOP2024000232A (es) 2024-12-30
EP4522129A1 (en) 2025-03-19
TWI867526B (zh) 2024-12-21

Similar Documents

Publication Publication Date Title
TWI867526B (zh) Glp1醫藥組合物
JP2021178871A (ja) エンザルタミドの製剤
CN101600419B (zh) 含有瑞伐拉赞的固体分散体以及其制备方法
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
TW201446286A (zh) 抗病毒化合物之固態分散調製劑
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
EP1039909A1 (en) Method and composition of an oral preparation of itraconazole
WO2012043709A1 (ja) 難溶性薬物の溶解性改善製剤
JP2025516547A (ja) Ｇｌｐ１錠剤組成物
CN107661302A (zh) 一种口服固体制剂及其应用
JP3037393B2 (ja) 経口投与用固形薬剤の製造方法
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
CN110452156B (zh) 多奈哌齐与厄贝沙坦共晶物及制备方法和其组合物与用途
JP2017200958A (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
WO2024136768A1 (en) Stable pharmaceutical compositions comprising amorphous tolvaptan
AU2023399904A1 (en) Solid dispersion comprising amorphous 2-[3-[4-(1h-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
WO2007102038A1 (en) Ziprasidone formulations
TR2024007612T2 (tr) Amorf tolvaptan i̇çeren formülasyonlar i̇çi̇n i̇yi̇leşti̇ri̇lmi̇ş üreti̇m yöntemi̇
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
JP2018009032A (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
TW201247246A (en) Dronedarone solid dispersion and its preparation method
SI22571A (sl) Stabilen trden farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive oblike

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination